Quintiles announced the release of Quintiles Infosario, a business-to-business platform that enables customers to leverage data for improved collaboration and decision-making throughout the drug development process.
“Quintiles Infosario is a fully integrated platform that enables significant advances in the drug development process,” said Tom Grundstrom, Quintiles Infosario Global Head. “The technology makes it possible to turn the wealth of data that our company possesses into actionable insights for our customers. Through the platform’s intuitive user interface, key stakeholders will be able to make faster, better-informed decisions about the programs and therapies they are working on.”
Quintiles’ latest reporting and analytics technology integrates, synchronizes, and standardizes subject, operational and management data automatically across a multitude of systems. The platform transforms data and information into meaningful insights to Quintiles’ customers using a secure, web-based front end with a drill path from insight to clinical data. Quintiles Infosario’s reporting and analytics capabilities are among the first features that will be available to select customers beginning later this month.
In addition, customers can fulfill all or parts of their clinical IT system needs through Quintiles Infosario’s cloud-based Systems as a Service. Infosario combines IT provisioning, including configured systems with core clinical business process delivery. By using Systems as a Service, customers will have direct, cost-effective access to IT systems such as safety management and clinical trial management–the same systems that serve Quintiles business.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.